Physician profile
Robert E Fell
NPI 1366502817
$7,987.31
in general payments reported to CMS, 2019-2025
42 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,823 · 2022: $2,029 · 2023: $2,307 · 2024: $1,403 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,976 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.06 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,120.19 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,105.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $534.00 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.16 | 2021-2023 | Jardiance |
| Amgen INC. | $450.88 | 2021-2024 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $439.22 | 2021-2024 | |
| Lilly USA, LLC | $438.75 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $387.73 | 2021-2025 | Entyvio, Trintellix, Gattex |
| Astellas Pharma US INC | $321.95 | 2023-2024 | Myrbetriq, Veozah |
| Horizon Therapeutics Plc | $300.40 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $284.33 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $239.89 | 2021-2024 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $239.07 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $170.70 | 2022-2024 | Eliquis, Camzyos |
| Aimmune Therapeutics, INC. | $139.34 | 2024-2025 | Vowst, Zenpep |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $136.06 | 2024 | Rezdiffra |
| Biogen, INC. | $133.93 | 2021-2022 | |
| Pfizer INC. | $101.45 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.69 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.66 | 2023-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $68.36 | 2021 | |
| Sumitomo Pharma America, INC. | $66.24 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $63.28 | 2021-2022 | |
| Dexcom, INC. | $57.46 | 2023-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $50.62 | 2024-2025 | Interstim, Pillcam |
| Inari Medical, INC. | $39.26 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Axsome Therapeutics, INC. | $31.24 | 2024 | Auvelity |
| Exact Sciences Corporation | $30.19 | 2023-2024 | Cologuard Collection Kit |
| Vivus LLC | $29.64 | 2024-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $28.43 | 2024 | Dupixent |
| Janssen Biotech, INC. | $27.50 | 2025 | Simponi, Tremfya, Simponi Aria |
| Ardelyx, INC. | $26.38 | 2024 | Ibsrela |
| Lundbeck LLC | $22.41 | 2023 | Rexulti |
| Teleflex LLC | $20.76 | 2024 | Solesta |
| Shield Therapeutics INC | $19.24 | 2023 | Accrufer |
| Glaxosmithkline, LLC. | $19.04 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $18.70 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $16.66 | 2022 | |
| Tris Pharma INC | $16.53 | 2023 | Dyanavel Xr |
| Intercept Pharmaceuticals, INC. | $15.99 | 2025 | |
| Axonics, INC. | $14.75 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.